A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) [tanespimycin] in Advanced Medullary and Differentiated Thyroid Carcinoma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Tanespimycin (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 15 Feb 2017 Biomarkers information updated
- 22 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.